Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger
- PMID: 31167060
- PMCID: PMC6518950
- DOI: 10.1056/NEJMc1901535
Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger
Comment in
-
Hope and Humility for Azithromycin.N Engl J Med. 2019 Jun 6;380(23):2264-2265. doi: 10.1056/NEJMe1906459. N Engl J Med. 2019. PMID: 31167057 No abstract available.
-
Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I.N Engl J Med. 2019 Nov 28;381(22):2184. doi: 10.1056/NEJMc1910014. N Engl J Med. 2019. PMID: 31774978 No abstract available.
References
-
- O'Brien KS, Emerson P, Hooper PJ, et al. . Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 2018. - PubMed
-
- Keenan JD, Arzika AM, Abdou A, Maliki R, Kane S, Cook C, Lebas E, Lin Y, Ray KJ, O’Brien KS, Doan T, Oldenburg C, Emerson PM, Porco TC, Lietman TM. MORDOR II: Persistence of Benefit of Azithryomcin for Childhood Mortality. Submitted.
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical